Corbus Cystic Fibrosis Data May Justify Longer, Larger Study

Safety was the primary endpoint in a Phase II study for the inflammation-targeting drug anabasum, but Corbus believes an efficacy signal viewed outside of the secondary endpoints justifies further development.